DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Mipsagargin is an investigational drug.
There have been 6 clinical trials for Mipsagargin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2016.
The most common disease conditions in clinical trials are Glioblastoma, Carcinoma, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are GenSpera, Inc., John Wayne Cancer Institute, and [disabled in preview].
There are two US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Mipsagargin
|Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma||John Wayne Cancer Institute||Phase 2|
|Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma||GenSpera, Inc.||Phase 2|
|Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA||GenSpera, Inc.||Phase 2|
Top disease conditions for Mipsagargin
Top clinical trial sponsors for Mipsagargin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mipsagargin||Get Started Free||Methods of treating glioblastoma multiforme using ibudilast||MediciNova, Inc. (La Jolla, CA)||Get Started Free|
|Mipsagargin||Get Started Free||Methods of treating disorders with glycosylation defective proteins||CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Mipsagargin||European Patent Office||EP3558301||2036-12-22||Get Started Free|
|Mipsagargin||Japan||JP2020504721||2036-12-22||Get Started Free|
|Mipsagargin||World Intellectual Property Organization (WIPO)||WO2018119262||2036-12-22||Get Started Free|
|Mipsagargin||World Intellectual Property Organization (WIPO)||WO2018068051||2036-10-07||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|